[Current research progress and prospects in neoadjuvant therapy for prostate cancer]

Area of Science:

• Oncology
• Urology
• Male Reproductive System Health

Background:

• Prostate cancer is a leading malignancy of the urinary and male reproductive systems, with increasing incidence.
• Many Chinese patients are diagnosed at advanced stages, precluding timely surgical treatment.
• Neoadjuvant therapy has evolved as a critical treatment strategy for localized and locally advanced prostate cancer.

Purpose of the Study:

• To review the current landscape of neoadjuvant therapies for prostate cancer.
• To assess the impact of neoadjuvant approaches on pathological outcomes.
• To identify areas for future research regarding survival benefits and safety.

Main Methods:

• Review of established neoadjuvant therapeutic strategies.
• Analysis of pathological response enhancement, including downstaging rates.
• Discussion of ongoing research into survival and safety outcomes.

Main Results:

• Established neoadjuvant therapies include endocrine therapy (androgen deprivation therapy), chemotherapy, and combination regimens.
• These therapies have demonstrated efficacy in improving pathological responses and downstaging.
• Potential benefits for high-risk localized and locally advanced prostate cancer patients are highlighted.

Conclusions:

• Neoadjuvant therapies show promise in improving pathological outcomes for prostate cancer patients.
• The definitive impact on overall survival and metastasis-free survival requires further investigation.
• Additional research is essential to compare efficacy and safety profiles of different neoadjuvant approaches.